Toward a Universal Flu Vaccine
New Candidate Fights Back against the Flu’s Efforts to Undermine the Human Immune System
Cell Therapy Manufacturing: All Signs Point to Commercialization
As Milestones Are Reached, Best Practices Will Become Less Hazy
Seeking New Users for iSeq
The Changing Sequencing Landscape
Vaccine Industry Retools Itself for Speed
Vaccine Manufacturing Moves toward Mass Customization
For full access to this article login to GEN Select now.
Road to Antibiotic Approval Made Clearer
Regulatory Hurdles Are Higher, but a New Well-Defined Path Means We Know How High to Jump
- Antibiotic development has become a challenging therapeutic area. Shifting and evolving regulatory guidelines have made design of clinical trials difficult and the prospect for marketing approval fairly low. In addition, the short-term treatment regimens have made the sector relatively unattractive from a return on investment perspective, particularly for antibiotics ...
Not registered yet? Please fill out the form below and enjoy complimentary access to this and an exclusive collection of premium content and personalization features as a GEN Select insider. Learn More.
Get GEN Select Access Now
- Do not put any letters or characters here if you are not a spy program.